Photocure ASA

PHO

NO0010000045

Pharmaceuticals

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
55.4 ^NOK	+1.84%		+1.09%	-17.80%

Apr. 08	Photocure ASA Announces its Participation in the Congress, and Two Abstract Presentations at the 2024 European Association of Urology Congress in Paris, France	CI
Mar. 28	Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy	CI

Tranche Update on Photocure ASA (OB:PHO)'s Equity Buyback Plan announced on June 3, 2022.

August 08, 2023

From April 1, 2023 to May 3, 2023, the company has repurchased 0 shares, representing 0% for NOK 0 million. With this, the company has completed the repurchase of 29,435 shares, representing 0.11% for NOK 3.06 million under the buyback announced on June 3, 2022.

Latest news about Photocure ASA

Photocure ASA Announces its Participation in the Congress, and Two Abstract Presentations at the 2024 European Association of Urology Congress in Paris, France	Apr. 08	CI
Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy	Mar. 28	CI
Transcript : Photocure ASA, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Photocure ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Photocure Partner Wins Chinese Regulatory Nod for New Drug Application for Bladder Cancer Diagnosis Drug	Nov. 29	MT
Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China	Nov. 29	CI
Transcript : Photocure ASA, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Photocure ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Photocure Chairperson Leaves; Interim Successor Assumes Position	23-09-28	MT
Photocure ASA Announces Change of Board Composition	23-09-27	CI
Photocure Soars 38% as Cevira Meets Primary Endpoint in Late-stage Study	23-09-20	MT
Photocure Biopharma Partner Asieris' Late-stage Bladder Cancer Trial Hits Primary Endpoint	23-08-11	MT
Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint	23-08-11	CI
Transcript : Photocure ASA, Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Photocure ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Tranche Update on Photocure ASA (OB:PHO)'s Equity Buyback Plan announced on June 3, 2022.	23-08-08	CI
Photocure Partner Asieris Closes Patient Enrollment for Bladder Cancer Drug Trial in China	23-07-06	MT
Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China	23-07-05	CI
Transcript : Photocure ASA, Q1 2023 Earnings Call, May 10, 2023	23-05-10
Photocure ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Tranche Update on Photocure ASA (OB:PHO)'s Equity Buyback Plan announced on June 3, 2022.	23-05-09	CI
Photocure ASA's Equity Buyback announced on June 3, 2022, has expired with 29,435 shares, representing 0.11% for NOK 3.06 million.	23-05-02	CI
Photocure Asa Announces New Data Presented At EAU 2023 Highlight the Effects of Blue Light Cystoscopy in Bladder Cancer	23-03-13	CI
Transcript : Photocure ASA, Q4 2022 Earnings Call, Feb 23, 2023	23-02-23
Photocure ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI

Chart Photocure ASA

Duration

Period

More charts

Company Profile

Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Companyâs activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Photocure ASA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

55.4 NOK

Average target price

86 NOK

Spread / Average Target

+55.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHOTOCURE ASA	-17.80%	136M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Photocure ASA

Equities

PHO

NO0010000045

Pharmaceuticals

Tranche Update on Photocure ASA (OB:PHO)'s Equity Buyback Plan announced on June 3, 2022.

EPS Revisions